PATENT CLAIM ANALYSIS

Application Number: 16001318
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["514", "001000"]

Abstract:
The present disclosure in various embodiments teaches methods of treating patients in need of treatment with a Factor Xa inhibitor, and who are also concomitantly administered verapamil.

Claim (Index 16):
The method of  claim 1 , wherein the dose of rivaroxaban recommended for an otherwise identical patient who is not concomitantly administered verapamil is 15 mg, and\n the dose of rivaroxaban administered in step (b) ranges from about 1 mg to about 14.9 mg.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 94.0
- Lexical Diversity: 1.07407
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13128459', '13184704', '13454286', '13454255', '12688038']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7474886715136643
- 35 USC 102 Novelty (BERT): 0.5186450681058232
- Combined Prediction Score: 0.7246043111728802
- Mean Citation Score: 244.7395
- Max Citation Score: 258.22217
- Similarity Product: 165.1669133260703

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test